nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxycodone—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0371	0.0503	CbGbCtD
Oxycodone—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0371	0.0503	CbGbCtD
Oxycodone—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.032	0.0435	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.032	0.0435	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0311	0.0422	CbGbCtD
Oxycodone—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0311	0.0422	CbGbCtD
Oxycodone—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0307	0.0418	CbGbCtD
Oxycodone—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0281	0.0382	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0281	0.0382	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0281	0.0382	CbGbCtD
Oxycodone—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0281	0.0382	CbGbCtD
Oxycodone—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0278	0.0378	CbGbCtD
Oxycodone—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0278	0.0378	CbGbCtD
Oxycodone—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.024	0.0326	CbGbCtD
Oxycodone—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0233	0.0316	CbGbCtD
Oxycodone—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0211	0.0286	CbGbCtD
Oxycodone—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0211	0.0286	CbGbCtD
Oxycodone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0201	0.0272	CbGbCtD
Oxycodone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0189	0.0256	CbGbCtD
Oxycodone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0189	0.0256	CbGbCtD
Oxycodone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0171	0.0232	CbGbCtD
Oxycodone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0171	0.0232	CbGbCtD
Oxycodone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0147	0.02	CbGbCtD
Oxycodone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0143	0.0194	CbGbCtD
Oxycodone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0129	0.0175	CbGbCtD
Oxycodone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0129	0.0175	CbGbCtD
Oxycodone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0128	0.0173	CbGbCtD
Oxycodone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.012	0.0163	CbGbCtD
Oxycodone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.012	0.0163	CbGbCtD
Oxycodone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0147	CbGbCtD
Oxycodone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0147	CbGbCtD
Oxycodone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00936	0.0127	CbGbCtD
Oxycodone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00909	0.0123	CbGbCtD
Oxycodone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00822	0.0112	CbGbCtD
Oxycodone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00822	0.0112	CbGbCtD
Oxycodone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00788	0.0107	CbGbCtD
Oxycodone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00129	0.156	CbGeAlD
Oxycodone—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000632	0.0286	CbGpPWpGaD
Oxycodone—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000555	0.0251	CbGpPWpGaD
Oxycodone—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000529	0.0641	CbGeAlD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000491	0.0222	CbGpPWpGaD
Oxycodone—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000469	0.0212	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000431	0.0195	CbGpPWpGaD
Oxycodone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000425	0.0515	CbGeAlD
Oxycodone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000409	0.0496	CbGeAlD
Oxycodone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000408	0.0494	CbGeAlD
Oxycodone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000397	0.0481	CbGeAlD
Oxycodone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000393	0.0475	CbGeAlD
Oxycodone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000391	0.0473	CbGeAlD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000364	0.0165	CbGpPWpGaD
Oxycodone—OPRM1—blood—acquired immunodeficiency syndrome	0.000357	0.0432	CbGeAlD
Oxycodone—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000353	0.016	CbGpPWpGaD
Oxycodone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000344	0.0417	CbGeAlD
Oxycodone—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000332	0.015	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000329	0.0149	CbGpPWpGaD
Oxycodone—OPRD1—brain—acquired immunodeficiency syndrome	0.000325	0.0393	CbGeAlD
Oxycodone—OPRK1—brain—acquired immunodeficiency syndrome	0.000312	0.0377	CbGeAlD
Oxycodone—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00031	0.014	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000297	0.0135	CbGpPWpGaD
Oxycodone—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000291	0.0132	CbGpPWpGaD
Oxycodone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00029	0.0351	CbGeAlD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000289	0.0131	CbGpPWpGaD
Oxycodone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000279	0.0338	CbGeAlD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000269	0.0122	CbGpPWpGaD
Oxycodone—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000262	0.0119	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000261	0.0118	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000251	0.0114	CbGpPWpGaD
Oxycodone—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000246	0.0111	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000244	0.011	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000236	0.0107	CbGpPWpGaD
Oxycodone—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000228	0.0103	CbGpPWpGaD
Oxycodone—OPRM1—brain—acquired immunodeficiency syndrome	0.000222	0.0268	CbGeAlD
Oxycodone—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00022	0.00998	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00022	0.00995	CbGpPWpGaD
Oxycodone—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000215	0.00973	CbGpPWpGaD
Oxycodone—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000215	0.00973	CbGpPWpGaD
Oxycodone—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000209	0.00947	CbGpPWpGaD
Oxycodone—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000204	0.0246	CbGeAlD
Oxycodone—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.0002	0.00904	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0002	0.00903	CbGpPWpGaD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000199	0.00902	CbGpPWpGaD
Oxycodone—CYP3A5—blood—acquired immunodeficiency syndrome	0.000194	0.0235	CbGeAlD
Oxycodone—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000186	0.00841	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000184	0.00832	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00018	0.00817	CbGpPWpGaD
Oxycodone—CYP3A5—vagina—acquired immunodeficiency syndrome	0.00018	0.0218	CbGeAlD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000175	0.00792	CbGpPWpGaD
Oxycodone—CYP3A5—lung—acquired immunodeficiency syndrome	0.00017	0.0206	CbGeAlD
Oxycodone—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000169	0.00764	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000166	0.00752	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000161	0.00729	CbGpPWpGaD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000158	0.00716	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000158	0.00714	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000156	0.00707	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000156	0.00707	CbGpPWpGaD
Oxycodone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000153	0.0185	CbGeAlD
Oxycodone—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000152	0.00688	CbGpPWpGaD
Oxycodone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.00015	0.0182	CbGeAlD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000148	0.00669	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000146	0.0066	CbGpPWpGaD
Oxycodone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000146	0.0176	CbGeAlD
Oxycodone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000144	0.00653	CbGpPWpGaD
Oxycodone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000143	0.0173	CbGeAlD
Oxycodone—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00014	0.00635	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000137	0.00622	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000137	0.0062	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000137	0.0062	CbGpPWpGaD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000136	0.00616	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000134	0.00605	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000133	0.00603	CbGpPWpGaD
Oxycodone—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000132	0.00597	CbGpPWpGaD
Oxycodone—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000132	0.00597	CbGpPWpGaD
Oxycodone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00013	0.00589	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000129	0.00583	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000123	0.00558	CbGpPWpGaD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000123	0.00558	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000123	0.00556	CbGpPWpGaD
Oxycodone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000122	0.00554	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00012	0.00545	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000119	0.00538	CbGpPWpGaD
Oxycodone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000118	0.0143	CbGeAlD
Oxycodone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000116	0.0141	CbGeAlD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000116	0.00524	CbGpPWpGaD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000116	0.00524	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000116	0.00523	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000116	0.00523	CbGpPWpGaD
Oxycodone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000114	0.00516	CbGpPWpGaD
Oxycodone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000114	0.0138	CbGeAlD
Oxycodone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000113	0.00511	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000113	0.0051	CbGpPWpGaD
Oxycodone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000112	0.0136	CbGeAlD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000111	0.00505	CbGpPWpGaD
Oxycodone—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000474	CcSEcCtD
Oxycodone—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000474	CcSEcCtD
Oxycodone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000474	CcSEcCtD
Oxycodone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000473	CcSEcCtD
Oxycodone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000473	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00011	0.000471	CcSEcCtD
Oxycodone—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00011	0.00047	CcSEcCtD
Oxycodone—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00011	0.00047	CcSEcCtD
Oxycodone—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.00047	CcSEcCtD
Oxycodone—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.00047	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.00047	CcSEcCtD
Oxycodone—Cough—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000469	CcSEcCtD
Oxycodone—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000469	CcSEcCtD
Oxycodone—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000467	CcSEcCtD
Oxycodone—Pain—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000467	CcSEcCtD
Oxycodone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000466	CcSEcCtD
Oxycodone—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000109	0.000466	CcSEcCtD
Oxycodone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000466	CcSEcCtD
Oxycodone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000465	CcSEcCtD
Oxycodone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000108	0.000464	CcSEcCtD
Oxycodone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000108	0.000464	CcSEcCtD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000108	0.00489	CbGpPWpGaD
Oxycodone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000108	0.000463	CcSEcCtD
Oxycodone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000463	CcSEcCtD
Oxycodone—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000463	CcSEcCtD
Oxycodone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000108	0.000462	CcSEcCtD
Oxycodone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000108	0.000462	CcSEcCtD
Oxycodone—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000461	CcSEcCtD
Oxycodone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000461	CcSEcCtD
Oxycodone—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.00046	CcSEcCtD
Oxycodone—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.00046	CcSEcCtD
Oxycodone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000107	0.00486	CbGpPWpGaD
Oxycodone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.00046	CcSEcCtD
Oxycodone—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000459	CcSEcCtD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000107	0.00485	CbGpPWpGaD
Oxycodone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000458	CcSEcCtD
Oxycodone—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000458	CcSEcCtD
Oxycodone—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000458	CcSEcCtD
Oxycodone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000458	CcSEcCtD
Oxycodone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000456	CcSEcCtD
Oxycodone—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000456	CcSEcCtD
Oxycodone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000106	0.000455	CcSEcCtD
Oxycodone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000455	CcSEcCtD
Oxycodone—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000454	CcSEcCtD
Oxycodone—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000452	CcSEcCtD
Oxycodone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000451	CcSEcCtD
Oxycodone—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000105	0.00045	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000449	CcSEcCtD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000105	0.00474	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000105	0.00474	CbGpPWpGaD
Oxycodone—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000449	CcSEcCtD
Oxycodone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000448	CcSEcCtD
Oxycodone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000448	CcSEcCtD
Oxycodone—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000448	CcSEcCtD
Oxycodone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.000448	CcSEcCtD
Oxycodone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000447	CcSEcCtD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000104	0.00472	CbGpPWpGaD
Oxycodone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Oxycodone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Oxycodone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Oxycodone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000104	0.0047	CbGpPWpGaD
Oxycodone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000445	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000445	CcSEcCtD
Oxycodone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000445	CcSEcCtD
Oxycodone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.000445	CcSEcCtD
Oxycodone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000444	CcSEcCtD
Oxycodone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000443	CcSEcCtD
Oxycodone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000443	CcSEcCtD
Oxycodone—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000443	CcSEcCtD
Oxycodone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000441	CcSEcCtD
Oxycodone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000441	CcSEcCtD
Oxycodone—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000441	CcSEcCtD
Oxycodone—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000103	0.000441	CcSEcCtD
Oxycodone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000103	0.00044	CcSEcCtD
Oxycodone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.00044	CcSEcCtD
Oxycodone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000103	0.00044	CcSEcCtD
Oxycodone—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000439	CcSEcCtD
Oxycodone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000438	CcSEcCtD
Oxycodone—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000102	0.000438	CcSEcCtD
Oxycodone—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000437	CcSEcCtD
Oxycodone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000437	CcSEcCtD
Oxycodone—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000437	CcSEcCtD
Oxycodone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000102	0.00461	CbGpPWpGaD
Oxycodone—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000436	CcSEcCtD
Oxycodone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000435	CcSEcCtD
Oxycodone—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000435	CcSEcCtD
Oxycodone—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000434	CcSEcCtD
Oxycodone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000434	CcSEcCtD
Oxycodone—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000101	0.000433	CcSEcCtD
Oxycodone—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000432	CcSEcCtD
Oxycodone—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000432	CcSEcCtD
Oxycodone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000101	0.000431	CcSEcCtD
Oxycodone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000101	0.000431	CcSEcCtD
Oxycodone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000431	CcSEcCtD
Oxycodone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.0001	0.00043	CcSEcCtD
Oxycodone—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.0001	0.00454	CbGpPWpGaD
Oxycodone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.0001	0.000429	CcSEcCtD
Oxycodone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.000429	CcSEcCtD
Oxycodone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	9.97e-05	0.000427	CcSEcCtD
Oxycodone—Rash—Nelfinavir—acquired immunodeficiency syndrome	9.96e-05	0.000427	CcSEcCtD
Oxycodone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	9.95e-05	0.000427	CcSEcCtD
Oxycodone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	9.95e-05	0.000426	CcSEcCtD
Oxycodone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	9.94e-05	0.000426	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	9.94e-05	0.000426	CcSEcCtD
Oxycodone—Rash—Stavudine—acquired immunodeficiency syndrome	9.93e-05	0.000426	CcSEcCtD
Oxycodone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	9.92e-05	0.000425	CcSEcCtD
Oxycodone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	9.92e-05	0.000425	CcSEcCtD
Oxycodone—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	9.91e-05	0.000425	CcSEcCtD
Oxycodone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	9.9e-05	0.000424	CcSEcCtD
Oxycodone—Headache—Nelfinavir—acquired immunodeficiency syndrome	9.9e-05	0.000424	CcSEcCtD
Oxycodone—Headache—Stavudine—acquired immunodeficiency syndrome	9.87e-05	0.000423	CcSEcCtD
Oxycodone—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.86e-05	0.000423	CcSEcCtD
Oxycodone—Confusional state—Lamivudine—acquired immunodeficiency syndrome	9.85e-05	0.000422	CcSEcCtD
Oxycodone—Pain—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000422	CcSEcCtD
Oxycodone—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000422	CcSEcCtD
Oxycodone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.84e-05	0.000422	CcSEcCtD
Oxycodone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.82e-05	0.000421	CcSEcCtD
Oxycodone—Rash—Abacavir—acquired immunodeficiency syndrome	9.78e-05	0.000419	CcSEcCtD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.78e-05	0.00442	CbGpPWpGaD
Oxycodone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.77e-05	0.000419	CcSEcCtD
Oxycodone—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	9.77e-05	0.000419	CcSEcCtD
Oxycodone—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.77e-05	0.000419	CcSEcCtD
Oxycodone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	9.77e-05	0.00442	CbGpPWpGaD
Oxycodone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	9.77e-05	0.00442	CbGpPWpGaD
Oxycodone—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.76e-05	0.000418	CcSEcCtD
Oxycodone—Headache—Abacavir—acquired immunodeficiency syndrome	9.72e-05	0.000417	CcSEcCtD
Oxycodone—Infection—Lamivudine—acquired immunodeficiency syndrome	9.71e-05	0.000416	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.7e-05	0.000416	CcSEcCtD
Oxycodone—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.69e-05	0.000415	CcSEcCtD
Oxycodone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.68e-05	0.000415	CcSEcCtD
Oxycodone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.64e-05	0.00436	CbGpPWpGaD
Oxycodone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.63e-05	0.000413	CcSEcCtD
Oxycodone—Shock—Lamivudine—acquired immunodeficiency syndrome	9.61e-05	0.000412	CcSEcCtD
Oxycodone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.58e-05	0.000411	CcSEcCtD
Oxycodone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	9.57e-05	0.00041	CcSEcCtD
Oxycodone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	9.56e-05	0.00041	CcSEcCtD
Oxycodone—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.56e-05	0.00041	CcSEcCtD
Oxycodone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.54e-05	0.00432	CbGpPWpGaD
Oxycodone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.51e-05	0.000408	CcSEcCtD
Oxycodone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.51e-05	0.000408	CcSEcCtD
Oxycodone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.49e-05	0.000407	CcSEcCtD
Oxycodone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.49e-05	0.000407	CcSEcCtD
Oxycodone—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	9.48e-05	0.000406	CcSEcCtD
Oxycodone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	9.46e-05	0.000405	CcSEcCtD
Oxycodone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	9.45e-05	0.000405	CcSEcCtD
Oxycodone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.41e-05	0.000403	CcSEcCtD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.39e-05	0.00425	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.39e-05	0.00425	CbGpPWpGaD
Oxycodone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.38e-05	0.000402	CcSEcCtD
Oxycodone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9.38e-05	0.000402	CcSEcCtD
Oxycodone—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.37e-05	0.000402	CcSEcCtD
Oxycodone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.37e-05	0.000401	CcSEcCtD
Oxycodone—Nausea—Stavudine—acquired immunodeficiency syndrome	9.35e-05	0.000401	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.33e-05	0.0004	CcSEcCtD
Oxycodone—Anorexia—Lamivudine—acquired immunodeficiency syndrome	9.31e-05	0.000399	CcSEcCtD
Oxycodone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.26e-05	0.000397	CcSEcCtD
Oxycodone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.25e-05	0.000397	CcSEcCtD
Oxycodone—Nausea—Abacavir—acquired immunodeficiency syndrome	9.22e-05	0.000395	CcSEcCtD
Oxycodone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	9.2e-05	0.000394	CcSEcCtD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.19e-05	0.00416	CbGpPWpGaD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.19e-05	0.00416	CbGpPWpGaD
Oxycodone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.19e-05	0.000394	CcSEcCtD
Oxycodone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.18e-05	0.000393	CcSEcCtD
Oxycodone—Urticaria—Delavirdine—acquired immunodeficiency syndrome	9.14e-05	0.000392	CcSEcCtD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.14e-05	0.00413	CbGpPWpGaD
Oxycodone—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.13e-05	0.000391	CcSEcCtD
Oxycodone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.13e-05	0.000391	CcSEcCtD
Oxycodone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	9.13e-05	0.000391	CcSEcCtD
Oxycodone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	9.11e-05	0.00039	CcSEcCtD
Oxycodone—Pain—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.00039	CcSEcCtD
Oxycodone—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.00039	CcSEcCtD
Oxycodone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.1e-05	0.00039	CcSEcCtD
Oxycodone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.1e-05	0.00039	CcSEcCtD
Oxycodone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.07e-05	0.0041	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	9.06e-05	0.0041	CbGpPWpGaD
Oxycodone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.05e-05	0.000388	CcSEcCtD
Oxycodone—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	9.04e-05	0.00409	CbGpPWpGaD
Oxycodone—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.02e-05	0.000386	CcSEcCtD
Oxycodone—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.01e-05	0.000386	CcSEcCtD
Oxycodone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.9e-05	0.000382	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.9e-05	0.000382	CcSEcCtD
Oxycodone—CYP2D6—brain—acquired immunodeficiency syndrome	8.89e-05	0.0108	CbGeAlD
Oxycodone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.86e-05	0.00038	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.84e-05	0.000379	CcSEcCtD
Oxycodone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	8.84e-05	0.000379	CcSEcCtD
Oxycodone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.83e-05	0.000379	CcSEcCtD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	8.81e-05	0.00399	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.79e-05	0.00398	CbGpPWpGaD
Oxycodone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	8.77e-05	0.000376	CcSEcCtD
Oxycodone—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	8.77e-05	0.000376	CcSEcCtD
Oxycodone—Pain—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000375	CcSEcCtD
Oxycodone—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000375	CcSEcCtD
Oxycodone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.71e-05	0.000373	CcSEcCtD
Oxycodone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.71e-05	0.000373	CcSEcCtD
Oxycodone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.7e-05	0.000373	CcSEcCtD
Oxycodone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.7e-05	0.000373	CcSEcCtD
Oxycodone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.69e-05	0.000372	CcSEcCtD
Oxycodone—Rash—Zidovudine—acquired immunodeficiency syndrome	8.63e-05	0.00037	CcSEcCtD
Oxycodone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.63e-05	0.00037	CcSEcCtD
Oxycodone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.62e-05	0.00037	CcSEcCtD
Oxycodone—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.6e-05	0.000369	CcSEcCtD
Oxycodone—Headache—Zidovudine—acquired immunodeficiency syndrome	8.58e-05	0.000368	CcSEcCtD
Oxycodone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.51e-05	0.000365	CcSEcCtD
Oxycodone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.49e-05	0.000364	CcSEcCtD
Oxycodone—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.49e-05	0.00384	CbGpPWpGaD
Oxycodone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.48e-05	0.000363	CcSEcCtD
Oxycodone—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.45e-05	0.000362	CcSEcCtD
Oxycodone—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	8.44e-05	0.000362	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.44e-05	0.000362	CcSEcCtD
Oxycodone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.42e-05	0.000361	CcSEcCtD
Oxycodone—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.42e-05	0.000361	CcSEcCtD
Oxycodone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.41e-05	0.000361	CcSEcCtD
Oxycodone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.41e-05	0.000361	CcSEcCtD
Oxycodone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.38e-05	0.0038	CbGpPWpGaD
Oxycodone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.38e-05	0.000359	CcSEcCtD
Oxycodone—Pain—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000358	CcSEcCtD
Oxycodone—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000358	CcSEcCtD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.26e-05	0.00374	CbGpPWpGaD
Oxycodone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.26e-05	0.000354	CcSEcCtD
Oxycodone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.23e-05	0.00373	CbGpPWpGaD
Oxycodone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.23e-05	0.000353	CcSEcCtD
Oxycodone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.14e-05	0.000349	CcSEcCtD
Oxycodone—Urticaria—Saquinavir—acquired immunodeficiency syndrome	8.14e-05	0.000349	CcSEcCtD
Oxycodone—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.13e-05	0.000348	CcSEcCtD
Oxycodone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.1e-05	0.000347	CcSEcCtD
Oxycodone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.1e-05	0.000347	CcSEcCtD
Oxycodone—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.09e-05	0.000347	CcSEcCtD
Oxycodone—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	8.05e-05	0.000345	CcSEcCtD
Oxycodone—Rash—Indinavir—acquired immunodeficiency syndrome	8.03e-05	0.000344	CcSEcCtD
Oxycodone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.02e-05	0.000344	CcSEcCtD
Oxycodone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	7.99e-05	0.000342	CcSEcCtD
Oxycodone—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.98e-05	0.00361	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.98e-05	0.00361	CbGpPWpGaD
Oxycodone—Headache—Indinavir—acquired immunodeficiency syndrome	7.98e-05	0.000342	CcSEcCtD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.97e-05	0.00361	CbGpPWpGaD
Oxycodone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	7.95e-05	0.000341	CcSEcCtD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	7.94e-05	0.00359	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.92e-05	0.00359	CbGpPWpGaD
Oxycodone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.87e-05	0.000337	CcSEcCtD
Oxycodone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.84e-05	0.000336	CcSEcCtD
Oxycodone—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.8e-05	0.00353	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.77e-05	0.00352	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.77e-05	0.00352	CbGpPWpGaD
Oxycodone—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.76e-05	0.000333	CcSEcCtD
Oxycodone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.72e-05	0.000331	CcSEcCtD
Oxycodone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.72e-05	0.000331	CcSEcCtD
Oxycodone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.65e-05	0.000328	CcSEcCtD
Oxycodone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.64e-05	0.000327	CcSEcCtD
Oxycodone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.61e-05	0.000326	CcSEcCtD
Oxycodone—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.6e-05	0.00344	CbGpPWpGaD
Oxycodone—Rash—Efavirenz—acquired immunodeficiency syndrome	7.58e-05	0.000325	CcSEcCtD
Oxycodone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.58e-05	0.000325	CcSEcCtD
Oxycodone—Nausea—Indinavir—acquired immunodeficiency syndrome	7.56e-05	0.000324	CcSEcCtD
Oxycodone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.55e-05	0.000323	CcSEcCtD
Oxycodone—Headache—Efavirenz—acquired immunodeficiency syndrome	7.54e-05	0.000323	CcSEcCtD
Oxycodone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.53e-05	0.000323	CcSEcCtD
Oxycodone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.44e-05	0.00337	CbGpPWpGaD
Oxycodone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.43e-05	0.00336	CbGpPWpGaD
Oxycodone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.35e-05	0.00333	CbGpPWpGaD
Oxycodone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.35e-05	0.000315	CcSEcCtD
Oxycodone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.32e-05	0.000314	CcSEcCtD
Oxycodone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.28e-05	0.000312	CcSEcCtD
Oxycodone—Rash—Delavirdine—acquired immunodeficiency syndrome	7.26e-05	0.000311	CcSEcCtD
Oxycodone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.25e-05	0.000311	CcSEcCtD
Oxycodone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.25e-05	0.000311	CcSEcCtD
Oxycodone—Headache—Delavirdine—acquired immunodeficiency syndrome	7.21e-05	0.000309	CcSEcCtD
Oxycodone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	7.2e-05	0.000309	CcSEcCtD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.18e-05	0.00325	CbGpPWpGaD
Oxycodone—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.14e-05	0.000306	CcSEcCtD
Oxycodone—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.05e-05	0.00319	CbGpPWpGaD
Oxycodone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.04e-05	0.000302	CcSEcCtD
Oxycodone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.01e-05	0.0003	CcSEcCtD
Oxycodone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.01e-05	0.0003	CcSEcCtD
Oxycodone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7e-05	0.00317	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7e-05	0.00317	CbGpPWpGaD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.99e-05	0.00316	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.96e-05	0.00315	CbGpPWpGaD
Oxycodone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.91e-05	0.000296	CcSEcCtD
Oxycodone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.84e-05	0.00309	CbGpPWpGaD
Oxycodone—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.84e-05	0.000293	CcSEcCtD
Oxycodone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.00029	CcSEcCtD
Oxycodone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.77e-05	0.00029	CcSEcCtD
Oxycodone—Rash—Ritonavir—acquired immunodeficiency syndrome	6.71e-05	0.000288	CcSEcCtD
Oxycodone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.7e-05	0.000287	CcSEcCtD
Oxycodone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.7e-05	0.00303	CbGpPWpGaD
Oxycodone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.69e-05	0.000287	CcSEcCtD
Oxycodone—Headache—Ritonavir—acquired immunodeficiency syndrome	6.67e-05	0.000286	CcSEcCtD
Oxycodone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.67e-05	0.00302	CbGpPWpGaD
Oxycodone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.51e-05	0.000279	CcSEcCtD
Oxycodone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000277	CcSEcCtD
Oxycodone—Rash—Saquinavir—acquired immunodeficiency syndrome	6.46e-05	0.000277	CcSEcCtD
Oxycodone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.45e-05	0.000277	CcSEcCtD
Oxycodone—Headache—Saquinavir—acquired immunodeficiency syndrome	6.42e-05	0.000275	CcSEcCtD
Oxycodone—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.32e-05	0.000271	CcSEcCtD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.3e-05	0.00285	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.29e-05	0.00285	CbGpPWpGaD
Oxycodone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.21e-05	0.00281	CbGpPWpGaD
Oxycodone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.21e-05	0.000266	CcSEcCtD
Oxycodone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.18e-05	0.0028	CbGpPWpGaD
Oxycodone—Rash—Lamivudine—acquired immunodeficiency syndrome	6.16e-05	0.000264	CcSEcCtD
Oxycodone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.16e-05	0.000264	CcSEcCtD
Oxycodone—Headache—Lamivudine—acquired immunodeficiency syndrome	6.12e-05	0.000262	CcSEcCtD
Oxycodone—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.08e-05	0.000261	CcSEcCtD
Oxycodone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.07e-05	0.00275	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.92e-05	0.00268	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.92e-05	0.00268	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.91e-05	0.00267	CbGpPWpGaD
Oxycodone—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.8e-05	0.000249	CcSEcCtD
Oxycodone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.78e-05	0.00262	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.63e-05	0.00255	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.47e-05	0.00248	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.32e-05	0.00241	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.32e-05	0.00241	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.23e-05	0.00237	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	5.17e-05	0.00234	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.9e-05	0.00222	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.82e-05	0.00218	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.8e-05	0.00217	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.8e-05	0.00217	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.61e-05	0.00208	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.61e-05	0.00208	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.51e-05	0.00204	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.51e-05	0.00204	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.5e-05	0.00204	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	4.39e-05	0.00199	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.36e-05	0.00197	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.22e-05	0.00191	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.21e-05	0.0019	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.17e-05	0.00189	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.1e-05	0.00185	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.1e-05	0.00185	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.05e-05	0.00184	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.04e-05	0.00183	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.04e-05	0.00183	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.96e-05	0.00179	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.96e-05	0.00179	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.82e-05	0.00173	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	3.73e-05	0.00169	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.65e-05	0.00165	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.59e-05	0.00163	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.59e-05	0.00163	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.57e-05	0.00162	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.56e-05	0.00161	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.43e-05	0.00155	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.41e-05	0.00155	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.41e-05	0.00155	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.38e-05	0.00153	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.34e-05	0.00151	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.34e-05	0.00151	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.23e-05	0.00146	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	3.17e-05	0.00144	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.00141	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.09e-05	0.0014	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.09e-05	0.0014	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.07e-05	0.00139	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.04e-05	0.00137	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.04e-05	0.00137	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.01e-05	0.00136	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.96e-05	0.00134	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.85e-05	0.00129	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.00127	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.73e-05	0.00124	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.71e-05	0.00123	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.69e-05	0.00122	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.66e-05	0.0012	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.57e-05	0.00116	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.54e-05	0.00115	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.5e-05	0.00113	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.5e-05	0.00113	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.46e-05	0.00111	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.42e-05	0.0011	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.42e-05	0.0011	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.31e-05	0.00105	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.29e-05	0.00104	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.27e-05	0.00103	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.26e-05	0.00102	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.26e-05	0.00102	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.12e-05	0.00096	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.12e-05	0.00096	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.11e-05	0.000955	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.08e-05	0.000942	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.91e-05	0.000863	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.84e-05	0.000833	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.81e-05	0.000821	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.79e-05	0.000812	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.79e-05	0.000812	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000808	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.74e-05	0.000786	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.000751	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000734	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.61e-05	0.000731	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.59e-05	0.00072	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000709	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.48e-05	0.000668	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.45e-05	0.000658	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.42e-05	0.000644	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.000617	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.000608	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.32e-05	0.000599	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000556	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.2e-05	0.000544	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.58e-06	0.000434	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.53e-06	0.000432	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	9.01e-06	0.000408	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.4e-06	0.00038	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.36e-06	0.000378	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.1e-06	0.000321	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.07e-06	0.00032	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	6.51e-06	0.000295	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.63e-06	0.000255	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.94e-06	0.000224	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.63e-06	0.00021	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.17e-06	0.000189	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.03e-06	0.000137	CbGpPWpGaD
